Form 4: Kyverna Therapeutics Director Christi Shaw Acquires Stock Options

Director Christi Shaw acquired stock options for 66,592 shares of Kyverna Therapeutics common stock on September 16, 2024.

Summary

• On September 16, 2024, Christi Shaw, a director of Kyverna Therapeutics, acquired stock options to purchase 66,592 shares of the company's common stock.
• The exercise price of these options is $6.89 per share.
• The options vest monthly over three years, with full vesting occurring on the third anniversary of the grant date, contingent upon continuous service to the Issuer.
• The expiration date for these options is September 16, 2034.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing related to stock option grants. It's neutral in tone, reflecting a routine transaction. The sentiment is slightly positive as it indicates director's alignment with company success.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the options is contingent upon the Reporting Person's continuous service to the Issuer, incentivizing continued involvement with the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of management and shareholders.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.

Key Dates